The oral drug teriflunomide demonstrates short-term safety and reduces lesions in multiple sclerosis for up to one year when used in combination with interferon beta, according to a study presented here.
Treatment-emergent adverse events were similar to placebo for patients on combination therapy, and the relative risk reduction for gadolinium-enhancing lesions on active treatment was more than 80% at 1 year, compared to patients on interferon beta alone.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933